Print Version |
Net sales during the three months ended
CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 31.8% to
We experienced a loss from operations during the three months ended
As of
An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).
NAI, headquartered in
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, potential re-opening of our
SOURCE -
CONTACT –
Web site: https://www.nai-online.com
|
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
|||||||
(In thousands, except per share data) |
|||||||
(Unaudited) |
|||||||
Three Months Ended |
|||||||
|
|||||||
2023 |
2022 |
||||||
|
$ 33,969 |
100.0 % |
$ 43,127 |
100.0 % |
|||
Cost of goods sold |
30,832 |
90.8 % |
37,756 |
87.5 % |
|||
Gross profit |
3,137 |
9.2 % |
5,371 |
12.5 % |
|||
Selling, general & administrative expenses |
3,681 |
10.8 % |
3,829 |
8.9 % |
|||
INCOME FROM OPERATIONS |
(544) |
-1.6 % |
1,542 |
3.6 % |
|||
Other loss, net |
(340) |
-1.0 % |
(224) |
-0.5 % |
|||
INCOME BEFORE TAXES |
(884) |
-2.6 % |
1,318 |
3.1 % |
|||
Income tax expense |
(189) |
265 |
|||||
NET INCOME |
$ (695) |
$ 1,053 |
|||||
NET INCOME PER COMMON SHARE: |
|||||||
Basic: |
( |
|
|||||
Diluted: |
( |
|
|||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |
|||||||
Basic |
5,850 |
5,920 |
|||||
Diluted |
5,850 |
5,943 |
|
|||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||
(In thousands) |
|||
|
|
||
2023 |
2023 |
||
(Unaudited) |
|||
ASSETS |
|||
Cash and cash equivalents |
|
|
|
Accounts receivable, net |
9,751 |
7,022 |
|
Inventories, net |
23,304 |
29,694 |
|
Other current assets |
7,950 |
6,690 |
|
Total current assets |
57,754 |
57,010 |
|
Property and equipment, net |
53,971 |
53,841 |
|
Operating lease right-of-use assets |
45,651 |
20,369 |
|
Other noncurrent assets, net |
2,876 |
2,932 |
|
Total Assets |
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Accounts payable and accrued liabilities |
15,085 |
14,450 |
|
Line of Credit |
- |
- |
|
Mortgage note payable |
9,444 |
9,517 |
|
Operating lease liability |
46,908 |
21,413 |
|
Total Liabilities |
71,437 |
45,380 |
|
Stockholders' Equity |
88,815 |
88,772 |
|
Total Liabilities and Stockholders' Equity |
|
|
View original content:https://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2024-q1-results-301984063.html
SOURCE